Schneider Marc A, Rozy Adriana, Wrenger Sabine, Christopoulos Petros, Muley Thomas, Thomas Michael, Meister Michael, Welte Tobias, Chorostowska-Wynimko Joanna, Janciauskiene Sabina
Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Translational Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Front Oncol. 2022 Jan 31;12:772076. doi: 10.3389/fonc.2022.772076. eCollection 2022.
In the last decade, targeting the immune system became a promising therapy in advanced lung cancer stages. However, in a clinical follow-up, patient responses to immune checkpoint inhibitors widely differ. Peripheral blood is a minimally invasive source of potential biomarkers to explain these differences. We blindly analyzed serum samples from 139 patients with non-small cell lung cancer prior to anti-PD-1 or anti-PD-L1 therapies to assess whether baseline levels of albumin (ALB), alpha-1 acid glycoprotein (AGP), alpha1-antitrypsin (AAT), alpha2-macroglobulin (A2M), ceruloplasmin (CP), haptoglobin (HP), alpha1-antichymotrypsin (ACT), serum amyloid A (SAA), and high-sensitivity C-reactive protein (hs-CRP), have a predictive value for immunotherapy success. Disease progression-free survival (PFS) was calculated based on RECIST 1.1 criteria. A multivariate Cox regression analysis, including serum levels of acute-phase proteins and clinical parameters, revealed that higher pre-therapeutic levels of HP and CP are independent predictors of a worse PFS. Moreover, a combined panel of HP and CP stratified patients into subgroups. We propose to test this panel as a putative biomarker for assessing the success of immunotherapy in patients with NSCLC.
在过去十年中，针对免疫系统成为晚期肺癌阶段一种有前景的治疗方法。然而，在临床随访中，患者对免疫检查点抑制剂的反应差异很大。外周血是解释这些差异的潜在生物标志物的微创来源。我们在抗PD-1或抗PD-L1治疗前，对139例非小细胞肺癌患者的血清样本进行了盲法分析，以评估白蛋白（ALB）、α-1酸性糖蛋白（AGP）、α1-抗胰蛋白酶（AAT）、α2-巨球蛋白（A2M）、铜蓝蛋白（CP）、触珠蛋白（HP）、α1-抗糜蛋白酶（ACT）、血清淀粉样蛋白A（SAA）和高敏C反应蛋白（hs-CRP）的基线水平是否对免疫治疗成功具有预测价值。根据RECIST 1.1标准计算无疾病进展生存期（PFS）。一项包括急性期蛋白血清水平和临床参数的多变量Cox回归分析显示，治疗前较高的HP和CP水平是PFS较差的独立预测因素。此外，HP和CP的联合指标将患者分层为亚组。我们建议将该指标作为评估非小细胞肺癌患者免疫治疗成功的假定生物标志物进行检测。
